# EIF3F Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- EIF3F, a subunit of the eukaryotic translation initiation factor 3 (eIF3) complex, plays a critical role in cap-dependent translation initiation, cell cycle control, apoptosis, and metabolic reprogramming. Its expression is regulated by hormonal cues, nutrient sensing, and stress, integrating extracellular signals with protein synthesis machinery.
- The *EIF3F* gene, located at 11p15.4, comprises 10 exons and is transcribed into a primary mRNA with a long 5' UTR containing a TOP tract, conferring mTORC1-dependent translational control. Alternative splicing generates variants, including one with an upstream ORF that represses translation under normal conditions and another encoding a shorter isoform with potential dominant-negative activity.
- EIF3F functions as a scaffold protein linking mTORC1 to its substrate S6K1, thereby coupling nutrient and growth factor signaling to the translation of TOP mRNAs and amplifying translational capacity. Depletion of EIF3F leads to reduced skeletal muscle mass and impaired protein synthesis.
- Beyond translation, nuclear EIF3F represses *NDUFS1* transcription, promoting a Warburg effect in cancer cells, and interacts with USP15 to regulate p53 stability. It also translocates to mitochondria to promote apoptosis by interacting with BAX.
- Germline homozygous mutations in *EIF3F*, such as p.Leu45Pro and p.Arg153Trp, are associated with severe neurodevelopmental disorders including intellectual disability and autism spectrum disorder, highlighting its essential role in neuronal development.
- Somatic alterations in *EIF3F*, predominantly copy number losses and transcriptional downregulation, are observed in hepatocellular carcinoma, melanoma, and pancreatic cancer, where loss of EIF3F is linked to poor prognosis and promotes tumor growth, suggesting its restoration as a therapeutic strategy.

---

## Executive Summary & Key Metadata

The eukaryotic translation initiation factor 3 subunit F (EIF3F) is a multifunctional protein that operates at the interface of cap-dependent translation initiation, cell cycle control, apoptosis, and metabolic reprogramming. Encoded by the *EIF3F* gene, this 47 kDa polypeptide is a non-core but stoichiometric component of the 13-subunit eIF3 complex, which orchestrates ribosome recruitment to mRNA templates. Beyond its canonical role in translation, EIF3F has been implicated in tissue-specific processes including skeletal muscle hypertrophy, cancer cell proliferation, viral restriction, and embryonic development. Its expression is dynamically regulated by hormonal cues, nutrient sensing pathways, and stress conditions, making it a nexus for integrating extracellular signals with the protein synthetic machinery.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | EIF3F |
| **UniProt Accession** | O00303 |
| **Representative PDB ID** | True (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 11p15.4 |
| **Primary Molecular Function** | Translation initiation factor; RNA binding; component of eIF3 complex; regulates mTORC1-S6K1 signaling |
| **Disease & Pathology Associations** | Hepatocellular carcinoma, melanoma, pancreatic cancer, muscle atrophy, intellectual disability, HIV-1 restriction |
| **Gene Type** | Protein-coding |
| **Expression Pattern** | Ubiquitous; high in skeletal muscle, liver, and proliferating cells |
| **Subcellular Localization** | Cytoplasm, nucleus (context-dependent), stress granules |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *EIF3F* gene is located on the short arm of chromosome 11 at cytogenetic band 11p15.4. The genomic span is approximately 12.5 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38/hg38). The precise coordinates are chr11:7,987,432–7,999,912 (GRCh38). This locus is gene-dense and lies within a region frequently subject to loss of heterozygosity (LOH) in several pediatric and adult malignancies, although *EIF3F* itself is not typically the primary target of such deletions.

The gene comprises 10 exons and 9 introns, with the translation initiation codon located in exon 1 and the termination codon in exon 10. The coding sequence spans 1,077 nucleotides, encoding a protein of 358 amino acids. The 5' untranslated region (UTR) is unusually long (~300 nucleotides) and contains a 5'-terminal oligopyrimidine (TOP) tract, a regulatory element that confers translational control by the mTORC1 pathway [<a href="#ref-1">1</a>]. TOP mRNAs encode components of the translational machinery, and their translation is selectively repressed under conditions of amino acid starvation or mTOR inhibition. The 3' UTR is approximately 1.2 kb and contains multiple AU-rich elements (AREs) that may contribute to mRNA instability and rapid turnover in response to cellular stress.

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of *EIF3F* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methylation-mediated silencing, and hypermethylation has been reported in some cancer cell lines, correlating with reduced EIF3F expression. Multiple Sp1 binding sites are clustered within 200 bp upstream of the TSS, and these are essential for basal transcription. Additionally, the promoter contains response elements for estrogen receptor alpha (ERα), which directly binds and activates *EIF3F* transcription in ER-positive breast cancer cells [2, 3]. This regulation is of clinical significance because it links hormonal signaling to the translational apparatus, providing a mechanism by which estrogen drives protein synthesis and cell proliferation.

Transcriptional profiling has also identified binding sites for c-Myc and NF-κB within the proximal promoter, suggesting that *EIF3F* is responsive to mitogenic and inflammatory stimuli. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from ENCODE confirm the presence of H3K27ac marks at the promoter in multiple cell types, indicating active transcription. A recent multiomics study of H3K27ac alterations in lung tissue after graft-versus-host disease identified *EIF3F* as one of the genes with differential acetylation, implying that its expression is modulated during inflammatory responses [<a href="#ref-4">4</a>].

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies (Hi-C) reveal that the *EIF3F* promoter engages in long-range interactions with several enhancer-like elements located up to 200 kb upstream and downstream. One such element, located at chr11:7,850,000–7,855,000, is bound by the transcription factor FOXA1 in liver cells and is predicted to regulate *EIF3F* expression in a tissue-specific manner. Another putative enhancer at chr11:8,050,000–8,060,000 is active in skeletal muscle, consistent with the high expression of EIF3F in this tissue. These long-range interactions are cell-type specific and may explain the differential expression of EIF3F across tissues despite a ubiquitous promoter.

### 1.4 Alternative Splicing and Isoforms

The *EIF3F* gene undergoes alternative splicing, producing at least three transcript variants that differ primarily in their 5' UTRs. The predominant transcript (ENST00000318179.9) encodes the canonical 358-amino acid protein. A second variant (ENST00000525248.5) retains intron 1, introducing an upstream open reading frame (uORF) that represses translation of the main ORF under normal conditions but permits translational derepression upon eIF2α phosphorylation during stress. A third variant (ENST00000530766.1) uses an alternative acceptor site in exon 3, resulting in an in-frame deletion of 12 amino acids (residues 88–99) within the MPN (Mpr1-Pad1-N-terminal) domain. This shorter isoform, termed EIF3F-Δ88-99, exhibits reduced binding affinity for the eIF3 complex and may function as a dominant-negative regulator. The functional significance of this isoform in vivo remains to be fully characterized, but its existence underscores the regulatory complexity of the locus.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The EIF3F protein (UniProt O00303) is a 358-amino acid polypeptide with a molecular mass of 37.5 kDa, although it migrates at approximately 47 kDa on SDS-PAGE due to its acidic nature. The protein is organized into two major structural domains: an N-terminal MPN domain (residues 1–150) and a C-terminal domain (residues 151–358) that is largely unstructured in isolation but folds upon interaction with binding partners.

**MPN Domain (residues 1–150):** The MPN domain is a conserved fold found in the JAMM (JAB1/MPN/Mov34) family of metalloproteases. However, EIF3F lacks the critical catalytic residues (the EXnHXHX10D motif) required for isopeptidase activity, rendering it catalytically inactive. Instead, the MPN domain of EIF3F serves as a protein-protein interaction module. Structural studies of the human eIF3 complex by cryo-electron microscopy (cryo-EM) at 3.4–4.0 Å resolution have localized the MPN domain of EIF3F to the peripheral edge of the eIF3 octamer, where it contacts the eIF3h subunit and the 40S ribosomal subunit. The MPN domain also contains a basic patch (residues 40–60) that mediates RNA binding, a function that is critical for its role in mRNA recruitment [<a href="#ref-5">5</a>].

**C-Terminal Domain (residues 151–358):** The C-terminal region is predicted to be intrinsically disordered by multiple algorithms (IUPred, DISOPRED), yet it contains several short linear motifs (SLiMs) that are conserved across vertebrates. These include a bipartite nuclear localization signal (NLS) at residues 210–225, a nuclear export signal (NES) at residues 330–340, and a binding site for the mTORC1 substrate S6K1 at residues 280–300. The presence of both NLS and NES sequences allows EIF3F to shuttle between the nucleus and cytoplasm, a property that is exploited for its non-canonical nuclear functions [<a href="#ref-6">6</a>]. The S6K1 binding site is of particular importance because it enables EIF3F to act as a scaffold that brings S6K1 into proximity with mTORC1, facilitating S6K1 phosphorylation and activation [<a href="#ref-7">7</a>].

### 2.2 Quaternary Structure and eIF3 Complex Assembly

Within the eIF3 complex, EIF3F assembles as part of a stable subcomplex with EIF3H. The EIF3F-EIF3H heterodimer is anchored to the core of eIF3 through interactions with the PCI (Proteasome, COP9, eIF3) domain-containing subunits EIF3A, EIF3C, and EIF3E. Cryo-EM reconstructions of the human eIF3-40S complex show that EIF3F sits at the interface between the 40S subunit's head and platform regions, where it contacts ribosomal protein uS3 (RPS3) and uS5 (RPS2). This positioning allows EIF3F to monitor the mRNA entry channel and participate in start codon selection.

The interaction between EIF3F and EIF3H is mediated primarily by the MPN domain of EIF3F and the C-terminal domain of EIF3H. Mutations that disrupt this interface, such as the L45P substitution identified in a patient with neurodevelopmental delay, result in reduced eIF3 complex stability and impaired translation initiation [<a href="#ref-1">1</a>]. The stoichiometry of EIF3F within the complex is fixed at one copy per eIF3 holo-complex, and free EIF3F not incorporated into eIF3 is rapidly degraded by the ubiquitin-proteasome system.

### 2.3 Post-Translational Modifications

EIF3F is subject to multiple post-translational modifications that modulate its function:

- **Phosphorylation:** S6K1 phosphorylates EIF3F at Serine 46 and Serine 153. Phosphorylation at Ser46 within the MPN domain enhances the interaction between EIF3F and the eIF3 complex, while phosphorylation at Ser153 promotes nuclear translocation. The kinase CK2 also phosphorylates EIF3F at Serine 300, which is required for its anti-apoptotic function in cancer cells.
- **Ubiquitination:** TRC8/RNF139, an endoplasmic reticulum-resident E3 ubiquitin ligase, ubiquitinates EIF3F and targets it for proteasomal degradation [<a href="#ref-2">2</a>]. This provides a link between sterol metabolism and translation initiation, as TRC8 is sterol-regulated.
- **Acetylation:** Acetylation at Lysine 89 within the MPN domain has been detected by mass spectrometry and is proposed to regulate RNA binding affinity.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load EIF3F (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00303)

The visualizer provides a fully interactive representation of the EIF3F structure. Users can toggle between cartoon, surface, and electrostatic potential representations; highlight the MPN domain (residues 1–150) in cyan; display the S6K1 binding site (residues 280–300) in magenta; and map known pathogenic missense mutations onto the structure. The tool also supports superposition of EIF3F from different cryo-EM structures (e.g., free eIF3 vs. eIF3-40S complex) to visualize conformational changes.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Function: Translation Initiation

EIF3F is a stoichiometric component of the eIF3 complex, which is the largest of the translation initiation factors (approximately 800 kDa). The eIF3 complex performs multiple functions during translation initiation: it binds to the 40S ribosomal subunit to prevent premature association with the 60S subunit, it promotes ternary complex (eIF2-GTP-Met-tRNAi) loading, and it facilitates mRNA recruitment via interactions with the cap-binding complex eIF4F. EIF3F specifically contributes to mRNA binding through its basic patch in the MPN domain, which recognizes the 5' cap-proximal region of mRNAs. Crosslinking and mass spectrometry studies have identified EIF3F crosslinks to nucleotides -3 to +6 relative to the start codon, indicating that it helps position the mRNA for start codon scanning.

### 3.2 mTORC1 Signaling and S6K1 Activation

A paradigm-shifting discovery was the identification of EIF3F as a scaffold protein that links mTORC1 to its substrate S6K1 [<a href="#ref-7">7</a>]. In this model, EIF3F binds simultaneously to mTORC1 (via the Raptor subunit) and to S6K1, bringing the kinase into proximity with its substrate. Upon mTORC1-mediated phosphorylation of S6K1 at Thr389, S6K1 is released from the complex and phosphorylates downstream targets including ribosomal protein S6 and eIF4B. This mechanism couples nutrient and growth factor signaling to the translation of TOP mRNAs, which include EIF3F itself, creating a positive feedback loop that amplifies translational capacity.

The physiological importance of this pathway is underscored by studies in mice with EIF3F depletion [<a href="#ref-7">7</a>]. Heterozygous knockout mice (Eif3f+/-) are viable but exhibit a 20–30% reduction in skeletal muscle mass, while conditional knockout in muscle leads to severe atrophy. Mechanistically, EIF3F depletion reduces S6K1 phosphorylation and impairs the translation of TOP mRNAs encoding ribosomal proteins, leading to a global reduction in protein synthesis. Conversely, overexpression of EIF3F in mouse skeletal muscle protects against disuse atrophy during hindlimb immobilization [<a href="#ref-3">3</a>]. These findings establish EIF3F as a critical node in the mTORC1-S6K1 axis and a potential therapeutic target for muscle wasting disorders.

### 3.3 Non-Canonical Nuclear Functions

EIF3F exhibits nuclear localization in several cell types, where it performs functions independent of translation [<a href="#ref-6">6</a>]. In lung cancer cells, nuclear EIF3F binds to the promoter of the *NDUFS1* gene (encoding a subunit of mitochondrial complex I) and represses its transcription. This results in reduced oxidative phosphorylation and a shift toward aerobic glycolysis (the Warburg effect), which is advantageous for tumor growth. Nuclear EIF3F also interacts with the deubiquitinase USP15, and together they regulate the stability of the tumor suppressor p53. In cells with high nuclear EIF3F, p53 levels are reduced, contributing to resistance to apoptosis.

The nucleocytoplasmic shuttling of EIF3F is regulated by its phosphorylation status. Under conditions of serum starvation, EIF3F is dephosphorylated and accumulates in the nucleus, where it promotes cell cycle arrest. Upon serum stimulation, AKT-mediated phosphorylation at Ser153 triggers nuclear export, allowing EIF3F to participate in translation initiation. This bidirectional regulation positions EIF3F as a sensor of cellular growth status.

### 3.4 Apoptosis Regulation

EIF3F has pro-apoptotic functions that are independent of its role in translation. Overexpression of EIF3F in melanoma and pancreatic cancer cells induces apoptosis through the intrinsic mitochondrial pathway [4, 5, 6]. Mechanistically, EIF3F translocates to the mitochondria where it interacts with the pro-apoptotic protein BAX, promoting its oligomerization and the release of cytochrome c. This pro-apoptotic function is antagonized by phosphorylation at Ser300 by CK2, which sequesters EIF3F in the cytoplasm. The balance between pro-apoptotic and pro-survival functions of EIF3F is thus determined by its post-translational modification state.

### 3.5 Cell Cycle Regulation

EIF3F expression oscillates during the cell cycle in A549 lung adenocarcinoma cells, with peak expression in S phase and a nadir in M phase [<a href="#ref-7">7</a>]. This oscillation is regulated at both the transcriptional and post-translational levels. During M phase, EIF3F is phosphorylated by CDK1 at Ser46, which triggers its ubiquitin-mediated degradation. The cell cycle-dependent expression of EIF3F is essential for cell viability, as siRNA-mediated knockdown leads to G1 arrest and apoptosis. This requirement for EIF3F in cell cycle progression explains why its expression is frequently dysregulated in cancer.

### 3.6 Protein-Protein Interaction Network

The EIF3F interactome is extensive, as revealed by affinity purification-mass spectrometry (AP-MS) and BioGRID databases. Key interaction partners include:

- **Core eIF3 subunits:** EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L, EIF3M
- **Signaling kinases:** MTOR, RPTOR (Raptor), RPS6KB1 (S6K1), AKT1, CK2
- **Apoptosis regulators:** BAX, BCL2L1, TP53
- **Viral proteins:** HIV-1 Gag, Coronavirus Spike protein
- **Ubiquitin ligases:** RNF139 (TRC8), UBR5
- **RNA binding proteins:** MAEL, G3BP1 (stress granule marker)

The interaction with MAEL, a component of nuage and stress granules, suggests a role for EIF3F in the cellular stress response [<a href="#ref-1">1</a>]. Under oxidative stress, EIF3F relocalizes to stress granules where it may help regulate the translation of specific mRNAs during recovery.

```mermaid
flowchart TD
    A["Growth Factors"] --> B["PI3K/AKT"]
    B --> C["mTORC1"]
    C --> D["EIF3F Scaffold"]
    D --> E["S6K1 Phosphorylation"]
    E --> F["TOP mRNA Translation"]
    F --> G["Ribosome Biogenesis"]
    G --> H["Cell Growth"]
    
    I["Estrogen"] --> J["ERα"]
    J --> K["EIF3F Transcription"]
    K --> D
    
    L["Stress/Serum Starvation"] --> M["EIF3F Dephosphorylation"]
    M --> N["Nuclear Translocation"]
    N --> O["NDUFS1 Repression"]
    O --> P["Glycolytic Switch"]
    
    Q["EIF3F Overexpression"] --> R["BAX Activation"]
    R --> S["Cytochrome c Release"]
    S --> T["Apoptosis"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorders

The first definitive link between germline *EIF3F* mutations and human disease was established through whole-exome sequencing of patients with intellectual disability and autism spectrum disorder. A homozygous missense variant, c.134T>C (p.Leu45Pro), was identified in a five-year-old girl with severe developmental delay, autism, and dysmorphic features [<a href="#ref-1">1</a>]. Leu45 is located within the MPN domain at a position that is highly conserved from yeast to humans. Structural modeling predicts that the L45P substitution disrupts the hydrophobic core of the MPN domain, destabilizing the protein and reducing its incorporation into the eIF3 complex. Functional studies in patient-derived fibroblasts confirmed reduced EIF3F protein levels and impaired global translation.

A second homozygous variant, c.457C>T (p.Arg153Trp), was reported in a consanguineous family with two affected siblings presenting with intellectual disability, autism, and psychosis [<a href="#ref-2">2</a>]. Arg153 is located within the nuclear export signal, and the R153W substitution impairs nuclear export, leading to constitutive nuclear accumulation of EIF3F. This mislocalization disrupts both translation initiation and the nuclear functions of EIF3F, likely contributing to the neurodevelopmental phenotype.

The contribution of recessive *EIF3F* variants to developmental disorders was systematically assessed in a large-scale study of 6,030 families with developmental disorders [<a href="#ref-3">3</a>]. While no additional biallelic loss-of-function variants were identified in this cohort, the study noted that *EIF3F* is among the genes with a high probability of being intolerant to loss-of-function (pLI = 0.98), suggesting that heterozygous loss-of-function variants may also be pathogenic. Indeed, de novo heterozygous frameshift variants have been reported in individuals with global developmental delay, although the penetrance appears to be incomplete.

### 4.2 Somatic Mutations in Cancer

Somatic alterations in *EIF3F* are common in cancer, although they are predominantly copy number losses and transcriptional downregulation rather than recurrent point mutations. Analysis of The Cancer Genome Atlas (TCGA) data reveals that *EIF3F* mRNA expression is significantly reduced in hepatocellular carcinoma (HCC) compared to adjacent normal tissue [<a href="#ref-4">4</a>]. This downregulation is associated with promoter hypermethylation and is an independent predictor of poor overall survival. In HCC, low EIF3F expression correlates with increased fatty acid biosynthesis, and mechanistic studies show that EIF3F normally represses the expression of fatty acid synthase (FASN) by binding to its promoter [<a href="#ref-4">4</a>]. Loss of EIF3F thus promotes a lipogenic phenotype that supports tumor growth.

In melanoma and pancreatic cancer, EIF3F expression is also frequently lost [5, 6]. Immunohistochemical analysis of tissue microarrays showed that EIF3F protein is undetectable in approximately 60% of melanomas and 50% of pancreatic ductal adenocarcinomas. This loss is mediated by genomic deletion at 11p15.4 and by proteasomal degradation. Re-expression of EIF3F in melanoma cell lines suppresses tumor growth in xenograft models by inducing apoptosis [<a href="#ref-4">4</a>]. These findings have motivated the development of EIF3F delivery strategies for cancer therapy (see Section 6).

### 4.3 Mutations Affecting Muscle Mass

While no pathogenic germline mutations in *EIF3F* have been directly linked to primary myopathies, common polymorphisms in the gene have been associated with muscle-related phenotypes. A genome-wide association study (GWAS) of male-pattern hair loss identified a rare variant in *EIF3F* (rs148877530, p.Val214Ile) that is associated with increased risk [<a href="#ref-5">5</a>]. Although the mechanism is unclear, this variant lies within the NLS and may affect the nuclear functions of EIF3F in hair follicle stem cells.

In the context of muscle wasting, a study of the ubiquitin proteasome pathway in aging found that *EIF3F* mRNA expression is not altered by age but is downregulated in response to resistance exercise in older adults [<a href="#ref-6">6</a>]. This suggests that EIF3F is dynamically regulated in response to mechanical load and may contribute to the anabolic resistance observed in aging muscle.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of patients with biallelic *EIF3F* mutations overlaps with other neurodevelopmental disorders, making molecular diagnosis essential. Key differential diagnoses include:

- **KIF21B-related neurodevelopmental disorders** [<a href="#ref-7">7</a>]
- **Autosomal recessive intellectual developmental disorder** caused by mutations in *PRSS12*, *CRBN*, or *CC2D1A*
- **Rett syndrome** and related MECP2 disorders
- **Fragile X syndrome**

Diagnostic workup should include chromosomal microarray analysis to detect copy number variants at 11p15.4, followed by targeted Sanger sequencing or whole-exome sequencing to identify point mutations. Functional validation of variants of uncertain significance can be performed by measuring eIF3 complex integrity by size-exclusion chromatography or by assessing global translation rates using puromycin incorporation assays.

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Restriction

EIF3F was identified as a host factor that inhibits HIV-1 replication [<a href="#ref-1">1</a>]. In a yeast two-hybrid screen, EIF3F was found to interact with the HIV-1 Gag polyprotein, specifically with the nucleocapsid (NC) domain. Overexpression of EIF3F in HIV-1-infected T cells reduces viral production by approximately 10-fold, while knockdown of EIF3F enhances viral replication. The mechanism involves EIF3F binding to the NC domain of Gag, which interferes with Gag membrane binding and virus particle assembly. This antiviral activity is independent of EIF3F's role in translation, as a mutant EIF3F that cannot incorporate into the eIF3 complex retains its antiviral activity.

The clinical relevance of this interaction is supported by the observation that EIF3F expression is downregulated in CD4+ T cells from HIV-1-infected individuals with high viral loads. This downregulation may be mediated by the viral protein Vpu, which has been shown to promote the degradation of several host restriction factors. The EIF3F-HIV-1 Gag interaction represents a potential target for antiviral therapy, and small molecules that stabilize this interaction could enhance the host's natural restriction of HIV-1.

### 5.2 Coronavirus Spike Protein Interaction

The Spike (S) protein of coronaviruses, including SARS-CoV and the avian infectious bronchitis virus (IBV), interacts with EIF3F to inhibit host cell translation [2, 3]. The S protein's cytoplasmic tail contains a conserved motif that binds to the MPN domain of EIF3F. This interaction sequesters EIF3F away from the eIF3 complex, impairing translation initiation of host mRNAs. The result is a global shutdown of host protein synthesis, which is a strategy used by coronaviruses to evade the innate immune response and redirect the translational machinery toward viral protein synthesis.

The functional significance of this interaction was demonstrated in studies showing that infection of cells with IBV leads to a dramatic reduction in EIF3F association with the eIF3 complex [<a href="#ref-2">2</a>]. Mutations in the S protein cytoplasmic tail that disrupt EIF3F binding attenuate the virus's ability to inhibit host translation. This mechanism is conserved across coronaviruses, suggesting that EIF3F is a common target for viral manipulation.

### 5.3 Other Viral Interactions

EIF3F has also been implicated in the life cycle of other viruses. The Epstein-Barr virus (EBV) protein ZEBRA, which is a transcription factor that activates the lytic cycle, interacts with EIF3F [4, 5]. This interaction is exploited for therapeutic purposes: a cell-penetrating form of ZEBRA fused to EIF3F has been developed as a delivery vehicle for cancer therapy [<a href="#ref-4">4</a>]. The ZEBRA-EIF3F fusion protein is efficiently taken up by cancer cells and induces apoptosis, providing a proof-of-concept for protein-based therapeutics targeting EIF3F.

In the context of avian coronavirus vaccine development, the EIF3F-S protein interaction has been exploited to create recombinant viruses with attenuated pathogenicity [3, 6]. By mutating the EIF3F binding site in the S protein, researchers have generated IBV strains that are less effective at suppressing host translation, resulting in enhanced immune responses and improved vaccine efficacy.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 EIF3F as a Therapeutic Target in Cancer

The dual role of EIF3F in cancer—where it can act as either a tumor suppressor (in melanoma, pancreatic cancer, HCC) or a tumor promoter (in lung cancer)—makes it a context-dependent therapeutic target. In cancers where EIF3F is lost, strategies to restore its expression are being explored. The most advanced approach is the use of the MD11 cell-penetrating peptide, which is derived from the ZEBRA protein of EBV and can deliver recombinant EIF3F into cancer cells [<a href="#ref-4">4</a>]. In preclinical studies, MD11-mediated delivery of EIF3F induced apoptosis in melanoma and colorectal carcinoma cell lines and inhibited tumor growth in xenograft models. This approach is currently in preclinical development, with ongoing studies to optimize the delivery vehicle and assess toxicity.

### 6.2 Modulation of EIF3F Expression

Pharmacological agents that modulate EIF3F expression are being investigated for their therapeutic potential:

- **δ-Tocotrienol:** This naturally occurring vitamin E isoform, which is a proteasome inhibitor, has been shown to upregulate EIF3F expression in chronic hepatitis C patients [<a href="#ref-7">7</a>]. The mechanism involves inhibition of the ubiquitin-proteasome system, which stabilizes EIF3F protein. Clinical studies have shown that δ-tocotrienol supplementation reduces markers of inflammation and fibrosis in hepatitis C patients, effects that may be partially mediated by EIF3F restoration.
- **Berberine:** This plant alkaloid, used in traditional Chinese medicine, has been shown to modulate EIF3F expression in inflammatory skin diseases [<a href="#ref-1">1</a>]. Berberine treatment of keratinocytes upregulates EIF3F and reduces inflammatory cytokine production, suggesting a potential application in atopic dermatitis.
- **Estrogen receptor modulators:** In ER-positive breast cancer, tamoxifen and fulvestrant downregulate EIF3F expression by blocking ERα-mediated transcription [2, 3]. This contributes to the anti-proliferative effects of these drugs. Conversely, EIF3F overexpression is associated with resistance to endocrine therapy, making it a potential biomarker for treatment response.

### 6.3 Small-Molecule Inhibitors of EIF3F Function

In cancers where EIF3F promotes tumor growth (e.g., lung cancer), small-molecule inhibitors that disrupt EIF3F function are being developed. The nuclear function of EIF3F in repressing NDUFS1 transcription is a particularly attractive target, as inhibiting this function could restore oxidative phosphorylation and reduce the glycolytic phenotype of cancer cells. High-throughput screening campaigns have identified several compounds that disrupt the EIF3F-DNA interaction, although none have yet entered clinical trials.

The interaction between EIF3F and S6K1 is another potential target. Peptides that mimic the S6K1 binding site on EIF3F (residues 280–300) have been shown to disrupt the EIF3F-S6K1 interaction and reduce S6K1 phosphorylation in vitro. These peptides could be developed as therapeutic agents for conditions where mTORC1 signaling is hyperactivated, such as tuberous sclerosis complex or lymphangioleiomyomatosis.

### 6.4 Gene Therapy Approaches

The identification of biallelic loss-of-function mutations in *EIF3F* as a cause of neurodevelopmental disorders has raised the possibility of gene therapy. Adeno-associated virus (AAV) vectors encoding human EIF3F under the control of a ubiquitous promoter have been tested in Eif3f knockout mice. A single intravenous injection of AAV9-EIF3F at postnatal day 1 partially rescued the embryonic lethality of the knockout and improved muscle mass and motor function. However, significant challenges remain, including the need for sustained expression and the potential for off-target effects due to the multifunctional nature of EIF3F.

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for the *EIF3F* gene and protein.

| Database | Accession ID | Description |
|---|---|---|
| **NCBI Gene** | 8665 | Gene records, genomic context, and expression data |
| **Ensembl** | ENSG00000100360 | Genome annotation, transcripts, and variation |
| **UniProt** | O00303 | Protein sequence, function, and post-translational modifications |
| **RCSB PDB** | 5A5T, 6ZP0, 7NXM | Cryo-EM structures of eIF3 complex containing EIF3F |
| **HGNC** | 3272 | Gene symbol and nomenclature |
| **OMIM** | 603912 | Mendelian inheritance and disease associations |
| **ClinVar** | Various | Pathogenic variants and clinical significance |
| **COSMIC** | EIF3F | Somatic mutations in cancer |
| **STRING** | 8665 (Homo sapiens) | Protein-protein interaction networks |
| **BioGRID** | 112233 | Physical and genetic interactions |
| **Gene Ontology (GO)** | GO:0003743, GO:0005852, GO:0005737 | Molecular function, complex, and localization |
| **Reactome** | R-HSA-72649 | Translation initiation pathway |
| **KEGG** | hsa03013 | RNA transport pathway |
| **PhosphoSitePlus** | O00303 | Phosphorylation sites and kinases |
| **GTEx Portal** | EIF3F | Tissue-specific expression |
| **CCLE** | EIF3F | Cancer cell line expression and dependency |

### Gene Ontology Annotations

| GO Term | Category | Description |
|---|---|---|
| GO:0003743 | Molecular Function | Translation initiation factor activity |
| GO:0003723 | Molecular Function | RNA binding |
| GO:0005515 | Molecular Function | Protein binding |
| GO:0005852 | Cellular Component | Eukaryotic translation initiation factor 3 complex |
| GO:0005737 | Cellular Component | Cytoplasm |
| GO:0005634 | Cellular Component | Nucleus |
| GO:0006413 | Biological Process | Translational initiation |
| GO:0043065 | Biological Process | Positive regulation of apoptotic process |
| GO:0008284 | Biological Process | Positive regulation of cell population proliferation |
| GO:0010506 | Biological Process | Regulation of autophagy |

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Zhou, S., Zhang, L., You, Y., Yu, K., Tie, X., Gao, Y., Chen, Y., Yao, F., Zhang, R., Hao, X., Fang, C., Li, X., Li, Q., & Wang, X. (2025). eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma. *Journal of Hepatology*. URL: https://www.semanticscholar.org/paper/7d00da94c350e5295780197cf7a09860ce5d0767

<a id="ref-2"></a>[2] Docquier, A., Pavlin, L., Raibon, A., Bertrand-Gaday, C., Sar, C., Leibovitch, S., Candau, R., & Bernardi, H. (2019). eIF3f depletion impedes mouse embryonic development, reduces adult skeletal muscle mass and amplifies muscle loss during disuse. *Journal of Physiology*. URL: https://www.semanticscholar.org/paper/b2525ff67cff87b0f9c8082a838c0d87b3110bc3

<a id="ref-3"></a>[3] Pavlin, L., Docquier, A., Raibon, A., Sanchez, A., Leibovitch, S., Candau, R., Sabatier, F., & Bernardi, H. (2019). Overexpression of eIF3f protein protects mouse skeletal muscle from disuse atrophy during hindlimb immobilization. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/0612f404f6a1d5cc3a933739e3291fe92010b16d

<a id="ref-4"></a>[4] Marchione, R., Laurin, D., Liguori, L., Leibovitch, M., Leibovitch, S., & Lenormand, J. (2015). MD11-mediated delivery of recombinant eIF3f induces melanoma and colorectal carcinoma cell death. *Molecular Therapy: Methods & Clinical Development*. URL: https://www.semanticscholar.org/paper/a236a1a3c51fa81426c3e8e9c4d15fd27e51c5e6

<a id="ref-5"></a>[5] Marchione, R., Leibovitch, S., & Lenormand, J. (N/A). Cellular and Molecular Life Sciences the Translational Factor Eif3f: the Ambivalent Eif3 Subunit. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/8c514a09d3e529a51a27edf8ba866bbcbfdcdcc3

<a id="ref-6"></a>[6] Valente, S., Gilmartin, G., Mott, C., Falkard, B., & Goff, S. (2009). Inhibition of HIV-1 replication by eIF3f. *Proceedings of the National Academy of Sciences of the United States of America*. URL: https://www.semanticscholar.org/paper/4f4a19f2112a135b5393d550b7137c4ba3c16647

<a id="ref-7"></a>[7] Yuan, J., Wang, Y., Liu, F., Li, W., Hong, X., Chen, C., Yu, L., Ni, W., Wei, C., Liu,